Galecto, Inc. is a clinical-stage biotechnology company that develops small molecules for the treatment of cancer and severe liver diseases. The company is built on nearly 15 years of research and is committed to pioneering a new class of medicines designed to bring safe and efficacious treatments for these conditions.
Focus Areas
Notable Investments
